140 related articles for article (PubMed ID: 36468967)
1. A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Wattanakrai P; Nimmannitya K
J Drugs Dermatol; 2022 Dec; 21(12):1304-1310. PubMed ID: 36468967
[TBL] [Abstract][Full Text] [Related]
2. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
Adalatkhah H; Sadeghi-Bazargani H
Drug Des Devel Ther; 2015; 9():4219-25. PubMed ID: 26345129
[TBL] [Abstract][Full Text] [Related]
3. Topical silymarin versus hydroquinone in the treatment of melasma: A comparative study.
Nofal A; Ibrahim AM; Nofal E; Gamal N; Osman S
J Cosmet Dermatol; 2019 Feb; 18(1):263-270. PubMed ID: 30146802
[TBL] [Abstract][Full Text] [Related]
4. Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: A split-face comparative study.
Tekam PS; Belgaumkar VA
Dermatol Ther; 2022 Nov; 35(11):e15761. PubMed ID: 36068674
[TBL] [Abstract][Full Text] [Related]
5. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma.
Sepaskhah M; Karimi F; Bagheri Z; Kasraee B
J Cosmet Dermatol; 2022 Jul; 21(7):2871-2878. PubMed ID: 35510765
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
Nguyen J; Remyn L; Chung IY; Honigman A; Gourani-Tehrani S; Wutami I; Wong C; Paul E; Rodrigues M
Australas J Dermatol; 2021 Feb; 62(1):e41-e46. PubMed ID: 32981068
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.
Lima PB; Dias JAF; Cassiano DP; Esposito ACC; Miot LDB; Bagatin E; Miot HA
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1881-1887. PubMed ID: 33988887
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma.
Ibrahim ZA; Gheida SF; El Maghraby GM; Farag ZE
J Cosmet Dermatol; 2015 Jun; 14(2):113-23. PubMed ID: 25847063
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up.
Lajevardi V; Ghayoumi A; Abedini R; Hosseini H; Goodarzi A; Akbari Z; Hedayat K
J Cosmet Dermatol; 2017 Jun; 16(2):235-242. PubMed ID: 27762489
[TBL] [Abstract][Full Text] [Related]
11. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
Grimes PE
Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial.
Gheisari M; Dadkhahfar S; Olamaei E; Moghimi HR; Niknejad N; Najar Nobari N
J Cosmet Dermatol; 2020 Jan; 19(1):167-172. PubMed ID: 31102345
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.
Yasnova N; Sirait SP; Rahmayunita G
Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):83-88. PubMed ID: 38918942
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
[TBL] [Abstract][Full Text] [Related]
16. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
Banihashemi M; Zabolinejad N; Jaafari MR; Salehi M; Jabari A
J Cosmet Dermatol; 2015 Sep; 14(3):174-7. PubMed ID: 26177992
[TBL] [Abstract][Full Text] [Related]
17. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
Shihab N; Prihartono J; Tovar-Garza A; Agustin T; Legiawati L; Pandya AG
Australas J Dermatol; 2020 Aug; 61(3):237-242. PubMed ID: 32109318
[TBL] [Abstract][Full Text] [Related]
18. Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma.
Taghavi F; Banihashemi M; Zabolinejad N; Salehi M; Jaafari MR; Marhamati H; Golnouri F; Dorri M
J Cosmet Dermatol; 2019 Jun; 18(3):870-873. PubMed ID: 30105847
[TBL] [Abstract][Full Text] [Related]
19. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
Basit A; Rahman A; Uddin R
J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
Mendoza CG; Singzon IA; Handog EB
Int J Dermatol; 2014 Nov; 53(11):1412-6. PubMed ID: 25265986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
